Hydralazine / isosorbide dinitrate Pregnancy and Breastfeeding Warnings

Hydralazine / isosorbide dinitrate is also known as: BiDil

Hydralazine / isosorbide dinitrate Pregnancy Warnings

Hydralazine-isosorbide dinitrate has been assigned to pregnancy category C by the FDA. Animal studies with hydralazine have revealed evidence of teratogenicity after doses 20 to 30 times the maximum recommended daily human dose (on a per kg basis) were given to mice. Teratogenicity was possibly related to hydralazine after doses 10 to 15 times the maximum recommended daily human dose (on a per kg basis) were given to rabbits. Animal studies have revealed evidence of embryotoxicity associated with isosorbide dinitrate at oral dosages 35 and 150 times the maximum recommended human daily dosage. There are no controlled data in human pregnancy on the use of either agent (alone or in combination). Hydralazine-isosorbide should only be given during pregnancy when benefit outweighs risk.

Hydralazine / isosorbide dinitrate Breastfeeding Warnings

There are no data on excretion of hydralazine-isosorbide dinitrate into human milk. The manufacturer recommends that caution be used when administering hydralazine-isosorbide dinitrate to nursing women.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web5)